AJMC Oral Peptides FAQ Mainstreams the Bioavailability and Safety Conversation Ahead of July PCAC
AJMC ran a consumer-grade FAQ on oral peptides covering bioavailability (typically <1% even with optimized formulations), delivery technologies (SNAC for oral semaglutide, liposomal systems, lipidation as in liraglutide and insulin detemir), and the safety distinction between FDA-approved oral peptides and the wave of unverified products. The piece sits alongside the AMA's late-April primer on injectable peptides and STAT, Scientific American, Washington Post, and ABC News coverage from earlier in the year — collectively building the public-facing safety narrative ahead of the July 23–24 PCAC meeting. The FAQ explicitly flags the FDA expert-panel review and the gap between Category 2 removal and FDA approval.